Business
Jazz Pharmaceuticals to Host Zanidatamab KOL Investor Webcast on June 2, 2023
Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT DUBLIN, May 25, 2023 /PRNewswire/ -- Jazz
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Zanidatamab data to be featured in oral presentation at ASCO 2023 Webcast to follow on June 2, 2023 at 6:45 p.m. CT\nDUBLIN, May 25, 2023 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) will host a webcast to review the zanidatamab biliary tract cancers (BTC) data being featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting on June 2, 2023. Previously disclosed positive top-line findings from the pivotal Phase 2b trial of zanidatamab as a monotherapy demonstrated a confirmed objective response rate (cORR) of 41.3% and median duration of response of 12.9 months in patients with previously treated HER2-positive BTC. The ASCO presentation will provide additional safety and efficacy data.\nShubham Pant, M.D., MBBS, a professor in the Department of Gastrointestinal Medical Oncology with a joint appointment in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center, will provide an overview of new data from the trial and Jazz senior management will discuss the development and commercialization of zanidatamab.\n\"There are currently no HER2-targeted therapies approved for patients with BTC; disease control with front-line therapy is modest and patients need treatment options after progression.i,ii Zanidatamab, a novel HER2-targeted bispecific antibody, is one of the most exciting and near-term programs in our pipeline, and the presentation at ASCO demonstrates its compelling anti-tumor effects in HER2-positive BTC. We are committed to advancing this program as rapidly as possible to potentially transform the lives of patients in critical need,\" said Rob Iannone, M.D., M.S.C.E., executive vice president, global head of research and development of Jazz Pharmaceuticals. \"With our impressive portfolio of oncology therapeutics approaching $1 billion in annual revenue, we remain focused on further enhancing our capabilities, advancing our pipeline and delivering treatments for difficult-to-treat cancers.\"\nWebcast DetailsThe webcast will start on June 2, 2023, at 6:45 p.m. CT / 7:45 p.m. ET / 12:45 a.m. IST (June 3). Interested parties may register for the webcast in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that par...